Acetazolamide (ACZ) is a carbonic anhydrase inhibitor that exhibits diuretic activity. In medicine, it is principally used in open-angle glaucoma, for prevention or amelioration of symptoms associated with acute high-altitude sickness and as an adjunct to other anticonvulsants in centrencephalic epilepsies. Furthermore, ACZ is sometimes used by athletes to mask the presence of doping substances, so its use has been banned in competitions.
INTRODUCTION

Acetazolamide (ACZ), N-[5-(aminosulfonyl)-1, 3, 4-thiadiazol-2-yl]
acetamide, is a carbonic anhydrase inhibitor that exhibits diuretic activity and decrease the formation of aqueous humor. In medicine, it is used principally in open-angle or secondary glaucoma, for prevention or amelioration of symptoms associated with acute high-altitude sickness (e.g., headache, lassitude, insomnia, nausea, shortness of breath, dizziness) and as an adjunct to other anticonvulsants in centrencephalic epilepsies (e.g., petit mal, unlocalized seizures) [1] . In addition to the therapeutic uses described above, athletes use this drug in order to mask the use of dopant substances. Since this diuretic drug increases urine flow and volume, other drugs that may have been used may decrease their plasma concentration drastically even below detection limits of suitable analytical methodologies, and may led to false negatives of doping substances. For this reason, this category of drugs has been included in the list of banned substances of the International Olympic Committee [2] .
Conventional methodologies for ACZ determination include polarography [3] , gas chromatography electron capture detector [4] and high performance liquid chromatography with ultraviolet detector [5] , which is the official method prescribed in the United States Pharmacopoeia [6] . These methods are usually expensive, complex, not environmental friendly and not suitable for real-time analyses. On the other hand, electroanalytical methodologies offer an attractive alternative of analysis due to low costs, simplicity, selectivity and high sensitivity. Many electrochemical methods have been reported in the literature to determine different drugs and pharmaceuticals, such as tramadol [7] , zafirlukast [8] , rosuvastatine [9] and acetaminophen [10] , among others, in pharmaceuticals and acrivastine [11] , norfloxacin [12] , levodopa [13] , cefixime [14] , amlodipine [15] in pharmaceuticals and biological matrix.
Recently, an electrochemical sensor based on MCPE-[Mn III/IV (µ-O) (phen) 2 ] 2 (ClO 4 ) 3 has been described for the determination of ACZ [16] .
Carbon nanofibers (CNFs) are filamentary materials mainly composed of graphitic carbon, with lengths in the order of micrometers and diameter in the order of tens of nanometers up to 200 nm. The decrease of the diameter has a positive effect on its physicochemical properties [17] . CNFs present beneficial chemical and physical properties for electrodes modifying and the development of sensors, such as high electrical conductivity, large surface area, easily functionalized, good electroanalytical properties, biocompatibles -it makes possible the enzymatic immobilization, and low electrical resistance [18] [19] . CNFs have a much larger functionalized surface area in comparison to carbon nanotubes, which allows a better immobilization and stabilization of biomolecules -enzymes, antibodies and DNA-. Due to the larger and controllable functionalized surface area of CNFs, one may even immobilize two or more different enzymes to develop enzymatic biosensors.
The novelty of this article is the development and optimization of a sensor based on carboxylated carbon nanofibers, to determine acetazolamide in pharmaceuticals and serum samples. The use of this electrodic modifier can lead to an enhanced detection limits methodology to determine uniformity of control in ACZ commercial tablets and be an alternative to the classic methods; moreover, this new methodology can allow to get lower detection limits for ACZ determination in serum samples.
EXPERIMENTAL
Apparatus and electrodes
Cyclic voltammetric (CV) and differential pulse voltammetric (DPV) experiments were carried out using a CHI821c potentiostat and software from CH Instrument, Austin, TX, USA. Determinations were performed in a conventional three-electrode cell, using the modified COOH-CNFs/ Glassy Carbon Electrode (GCE) as working electrode, and Ag/AgCl CHI128 as reference electrode and a platinum wire as counter electrode. pH measurements were performed with a Thermo combined glass electrode in HANNA pH meter, Smithfield, RI, USA. An Elmasonic ultrasonic bath was also used. All the experiments were carried out at room temperature.
Reagents
Acetazolamide, Na 2 HPO 4 ·H 2 O, NaH 2 PO 4 ·H 2 O, Carbon nanofibers graphitized, Nafion ® 117 solution, were purchased from Sigma-Aldrich (St. Louis, USA). Water was obtained from a Simplicity ® UV system, Millopore (Darmstadt, Germany).
Samples
Commercial tablets of Acetazolamide (declared amount per tablet: 250 mg, Mintlab S.A. laboratories, Chile) were purchased in a local drugstore. Analyzed samples were lyophilized human serum from Sigma spiked with acetazolamide in three concentration levels.
Procedures
Carbon nanofibers carboxylation
CNFs were carboxylated by treatment under ultrasonic stirring with a 3:1 mixture of sulfuric acid and nitric acid for 5 hours. This product was centrifuged at 14000 rpm and washed with ultrapure water up to pH 7 [20] . Then, five milligrams of COOH-CNFs were dispersed in 5 mL in ultrapure water, using ultrasonic stirring for 30 min.
Preparation of the modified electrode
The GCE surface was polished with 0.3 and 0.1 µm alumina slurries, rinsed thoroughly with ultrapure water, and sonicated for one minute with a 1:1 mixture of water and acetone. Then, a 10 µL aliquot of COOH-CNFs suspension was deposited onto the glassy carbon electrode surface and allowed to dry at 41 °C. Subsequently, 5 µL aliquot of Nafion ® 0.375 % was deposited onto the electrode surface and allowed to dry [21] . Finally, the modified electrode was washed with ultrapure water.
Determination of Acetazolamide in serum samples
Human serum was spiked with ACZ in order to have three concentration levels: 81.6, 68.0 and 54.4 µM. ACZ was determined by differential pulse voltammetry from 0.8 to 1.5 V, with a pulse width of 35 ms, pulse amplitude of 50 mV and a scan rate of 60 mVs -1 . These parameters were optimized (data not shown). Standard addition method was used as quantification method, implying successive additions of 5 µM ACZ standard solution.
Uniformity of content
20 tablets of ACZ (250 mg of ACZ per tablet) were weighed and finely powdered. 199.2 mg of the power (equivalent to 100 mg of ACZ) were transferred to a 100 mL volumetric flask, 10 mL of 0.5 N NaOH were added. Then, the solution was sonicated for 5 minutes and diluted with water to volume. A 10 mL aliquot of the solution was filtered and diluted to 100 mL with water. ACZ was determined by differential pulse voltammetry from (at the same experimental conditions than "Determination of Acetazolamide in serum samples"), and using the standard addition method implying successive additions of 5 µM ACZ.
RESULTS AND DISCUSSION
Preparation of the ACZ sensor
First, the electrochemical response of the CNF-GCE toward Fe(CN) 6 3-/4-redox couple was evaluated and compared with bare GCE response. Voltammograms in Fig. 1 shows that larger currents are exhibited when CNFs are used to modify a GCE. This is due to the high conductivity and large surface area of CNF, allowing a better electron transference. Thus, employing this modified electrode to determine certain analytes may lead to a higher sensitivity and, as a consequence, to lower detection limits. The supporting electrolyte has an essential function in electrochemical determinations, so Britton-Robinson buffer and phosphate buffer were compared. Figure 3 shows that greater anodic peaks and a greater slope was obtained when phosphate buffer was used. In addition, phosphate buffer capacity is greater than when using Britton-Robinson buffer at pH 7.0, which would prevent any pH change during the analysis. Yet, both buffer solutions can be used for the determinations. The effect of the pH on the voltammetric response for ACZ was evaluated over the 4.0 -9.0 range. For this purpose, 0.1 M Britton-Robinson buffer solutions at different pH were used. The anodic peak is shifted to the left when increasing the pH, which has to be taken in consideration at the moment of selecting the working pH in order to avoid some interfering (data not shown). Moreover, a sharp increase in the sensor response was observed at pH 7.0, which can be clearly seen in Figure 2 when calibrates slopes are compared; however, over pH 7.0, the anodic peak current decreases, especially at pH 9.0. Thus, pH 7.0 was chosen as a working pH for further work in order to get a higher sensitivity in the determinations. The influence of the surface modifier (COOH-CNFs) was also studied, comparing ACZ calibrate plots recorded at GCE modified with 5, 10, and 15 µL of 2 mg/mL COOH-CNFs suspension (data not shown). 10 µL was chosen because the highest anodic current was obtained with this amount of modifier. When modifying the electrodic surface with 15 µL, same anodic peak and greater levels of noise were gotten, probably due to the saturation of the electrodic surface with ACZ. 
Calibration graphs and analytical characteristics
Under optimized working conditions, analytical performance of COOHCNFs-GCE was evaluated by means of ACZ determinations and calibration plots in standard solutions. Figure 4 , left, displays the calibration graph for ACZ, with a slope of 1.14 ± 0.02 µA µM -1 and an intercept of -0.52 ± 0.009 µA, yielding a linear relationship (r 2 = 0.9989) within 1.0 -17.5 µM. This concentration range is appropriate for the determination of ACZ either in pharmaceuticals, according to its potency and after and adequate dilution, and serum samples, according to its serum concentrations. Figure 4 , right, shows the voltammograms that were used to plot the calibration graph. The detection limit (LOD) was estimated as 0.06 µM and was calculated according to 3sb/m criterion, where m is the slope of the linear portion of the calibration plot (1.0 -17.5 µM), and sb was calculated as the standard deviation (n=10) of the voltammetric signals measured for different ACZ solutions at the lowest concentration level of the calibration plot (1.0 µM). Besides, the limit of quantification (LOQ) was estimated as 0.2 µM, using the 10sb/m criterion. The precision of the analytical responses was also evaluated. For reproducibility, three different modified electrodes were used in three different laboratories, obtaining a relative standard deviation (RSD) of 3.2 % for the lowest concentration level analyzed. On the other hand, successive voltammetric measurements of ten independent 1.0 µM ACZ solutions were performed to obtained the repeatability of the methodology, obtaining an RSD value of 0.72 %. 
Determination of ACZ in pharmaceuticals and serum samples
The performance and effectiveness of this sensor based on CNFs towards the determination of ACZ either in pharmaceuticals and serum samples was studied by means of the analysis of both sort of matrices spiked with ACZ at three different levels: 80, 100 and 120 % of the declared potency (250 mg ACZ) for pharmaceuticals, and 54.4, 68.0, and 81.6 µM for serum samples. All runs were performed by standard addition method, adding an adequate aliquot of the sample to the electrochemical cell followed by three additions of 5 µM ACZ. For the determination of ACZ in serum samples (see Table 1a ), mean recovered obtained (n=5) ranged between 95.04 and 97.01 % with a relative standard deviation of 1.01 % (for the lowest concentration level). Furthermore, serum samples with no ACZ did not yield significant voltammetric responses when they were analyzed. For the determination of ACZ in placebo tablets, mean recovered obtained (n=5) ranged between 98.8 and 99.7 %, with an RSD of 1.1 % for the lowest concentration level. These data of accuracy can be seen in Table 1b . On the other hand, the results obtained for uniformity of content of ACZ 250 mg commercial tablets showed that they have 99.84 ± 0.23 % (249.59 ± 0.23 mg ACZ) of the declared content, which complies the pharmacopoeia limits, which says that "Acetazolamide tablets contain no less than 95.0% and no more than 105% of the labeled amountof acetazolamide" (5). Figure 5 shows the voltammograms of the determination of ACZ in commercial tablets. These results clearly demonstrate that this new methodology can be used for determining ACZ in pharmaceuticals and serum samples. 
CONCLUSION
An electrochemical methodology for acetazolamide determination, based on a modified electrode with carbon nanofibers, has been developed for the determination of this analyte in pharmaceuticals and human serum.
Results reported here show that carbon nanofibers provide a suitable platform to determine bioactive molecules, being a good approach to the development of enzymatic biosensors. Detection limit obtained for acetazolamide was 0.06 μM. The sensor showed excellent performance, such as low detection limit and high sensitivity, and is a feasible choice for the determination of acetazolamide in pharmaceuticals and human serum in order to applicate it in pharmaceutical quality control and doping analyzes, respectively.
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